Physician profile
Megan Abrams
NPI 1932561032
$4,318.88
in general payments reported to CMS, 2019-2025
9 companies · $39.02 in 2025
The $39.02 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2022: $1,234 · 2023: $1,817 · 2024: $625 · 2025: $39.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718 · Travel and Lodging: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.61 |
| Travel and Lodging | $763.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,961.35 | 2021-2025 | Advantage System, Solyx Sis System |
| Axonics, INC. | $786.74 | 2021-2023 | Axonics |
| Medtronic, INC. | $654.45 | 2021-2024 | Interstim, Ligasure, Nuro |
| Coloplast Corp | $390.66 | 2022-2024 | |
| Caldera Medical, INC | $184.04 | 2022-2023 | Desara |
| Abbvie INC. | $134.55 | 2022-2025 | |
| Coopersurgical, INC. | $108.73 | 2022-2023 | Summit Doppler |
| Astellas Pharma US INC | $79.45 | 2021-2022 | |
| Heron Therapeutics, INC. | $18.91 | 2024 | Zynrelef |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.